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Intrarenal complement activation plays an important role in
the progression of chronic kidney disease. A key target of the
activated complement cascade is the proximal tubule, a site
where abnormally filtered plasma proteins and complement
factors combine to promote injury. This study determined
whether protein overloading of human proximal tubular cells
(HK-2) in culture enhances complement activation by
impairing complement regulation. Addition of albumin or
transferrin to the cells incubated with diluted human serum
as a source of complement caused increased apical C3
deposition. Soluble complement receptor-1 (an inhibitor of
all 3 activation pathways) blocked complement deposition
while the classical and lectin pathway inhibitor, magnesium
chloride–EGTA, was, ineffective. Media containing albumin as
well as complement had additive proinflammatory effects as
shown by increased fractalkine and transforming growth
factor-b mRNA expression. This paralleled active C3 and
C5b-9 generations, effects not shared by transferrin. Factor H,
one of the main natural inhibitors of the alternative pathway,
binds to heparan sulfate proteoglycans. Both the density of
heparan sulfate and factor H binding were reduced with
protein loading, thereby enhancing the albumin- and
serum-dependent complement activation potential. Thus,
protein overload reduces the ability of the tubule cell to bind
factor H and counteract complement activation, effects
instrumental to renal disease progression.
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Progressive nephropathies with severe defects of the glomer-
ular filtration barrier to proteins are accompanied by
tubulointerstitial damage eventually contributing to loss of
renal function.1 The clinical problem has grown enormously1,2
and understanding the basic mechanisms is mandatory.
Experimental observations suggested that ultrafiltered plasma
proteins exert renal toxicity, which is partly mediated by
activation of inflammatory and fibrogenic pathways by
proximal tubular cells.3–9 Among processes underlying injury,
the activation of the complement cascade in the renal tubule
has major effects.10 Complement proteins can be abnormally
filtered across the altered glomerular barrier leading to
intratubular deposition of C3 and formation of membrane
attack complex (MAC).11–13 Proximal tubular epithelial cells
also synthesize most components of the activation cascade.14,15
Investigation using proteinuric models of glomerular injury
showed less tubulointerstitial damage in complement-depleted
rats12,13 and C6-deficient rats,16 or upon treatment with
complement inhibitory molecules.13,17 Inflammation and a
fibrogenic reaction ensue upon proximal tubule overloading
by C3 and ultrafiltered proteins in rats with remnant
kidneys.18,19 We have recently found that ultrafiltered
complement factors are a key component of proteinuria-
associated renal injury. Thus, plasma-derived C3 is recruited
with other ultrafiltered proteins in the tubular compartment to
mediate interstitial macrophage accumulation and renal
structural damage in the absence of C3 synthesis by the
kidney, in a mouse model of protein-overload proteinuria.20
Overall, proteinuria is required for complement to fully exert
harmful effects on the kidney,21 possibly by enhancing the
vulnerability of proximal tubular cells to luminal attack by
complement. This makes it difficult to dissect mechanisms by
which complement could be engaged with other ultrafiltered
proteins to induce tubular cell dysfunction. However,
approaches using cultured proximal tubular epithelial cells
are most appropriate to address this issue.
In human proximal tubular cells exposed to serum,
complement activation through the alternative pathway leads
to surface deposition of C3 and MAC and upregulation of
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cytokines.22,23 Complement activation might be dependent
on relative lack of complement inhibitors. Cell-associated
regulators at C3 level, decay accelerating factor and
membrane cofactor protein, are hardly detectable on apical
membranes of proximal tubular cells. Conversely, human
proximal tubular cells produce factor H,24 a 150-kDa plasma
glycoprotein acting as the major soluble inhibitor of the
formation of alternative pathway C3 convertase on the cell
surface25,26 and possibly representing a unique defense
mechanism against complement activation. No studies have
yet documented actual binding of factor H by tubular
epithelial cells. Relevant binding sites on the cell surface, as
shown in endothelial cells, may include heparan sulfate
proteoglycans.27
The aim of this study was to investigate whether (1)
protein overload may influence complement activation and
deposition on the surface of proximal tubular cells exposed to
serum complement, a condition that mimics the exposure of
tubular cells to ultrafiltered complement in proteinuric
disease; (2) this effect was related to reduced binding of
factor H on the cell surface accounting for reduced capability
of the cell to counteract complement activation; and (3) loss
of heparan sulfate sites contributed to reduced factor H
binding to the cell.
RESULTS
Protein overload enhances the activation of serum-derived
complement by human proximal tubular cells
With the aim of studying the effect of plasma protein
challenge on complement deposition, preliminary experi-
ments were carried out to identify the sublytic concentration
of human serum (HS), used as source of complement. Cell
viability, as assessed by trypan blue dye exclusion at 90 min,
was not affected by exposure to 10% HS, whereas a
significant (Po0.01) reduction was observed upon exposure
to 25% HS in comparison with control cells (10% HS: 91±5,
25% HS: 71±4 versus control: 100% viable cells). The
concentration of 10% HS was therefore established to be
sublytic. HK-2 cells upon exposure to 10% HS activated and
fixed C3 and MAC on the apical side of the cell surface as
showed by appearance of granular staining by immunofluor-
escence analysis (Figure 1) on cell surface. In contrast,
unstimulated cells showed no fluorescent signal (Figure 1).
Addition of sCR-1, a soluble inhibitor of all the three
pathways of complement activation, completely blocked C3/
MAC deposition on cell surface, indicating specificity of C3
and MAC signals (Figure 1). Similarly, no complement
protein deposition was detected using heat-inactivated HS
(data not shown).
To study whether protein overload could enhance the
ability of proximal tubular epithelial cells to fix complement
molecules, immunofluorescence analysis of C3 and MAC
deposits was performed on HK-2 cells, first challenged with
albumin or transferrin and then incubated with 10%
HS as described above. Both plasma proteins caused
significant increases in C3 staining as detected at the end of
the experiment, in comparison with cells exposed to HS
alone (Figure 2a). Exposure of HK-2 cells to plasma proteins
in the absence of HS resulted in no significant changes in C3
staining as compared with unstimulated cells, thus
excluding that the abnormal accumulation of C3 on the cell
surface in the presence of HS could be attributed to the
induction of C3 synthesis in response to albumin and
transferrin. To test whether complement activation may
occur through the alternative pathway, cells were incubated
with HS containing sCR-1 or with MgCl2–EGTA that blocks
the activation of the classic and the lectin pathways. The
addition of sCR-1 resulted in complete inhibition of C3
deposition. In contrast, MgCl2–EGTA had no significant
effect (Table 1).
C3
MAC
Control
Control
HS 10%
Inset
Inset
HS 10% HS 10% + sCR-1
HS 10% + sCR-1
Figure 1 | C3 and MAC (membrane attack complex) deposition on tubular epithelial cell surface in response to human serum (HS).
Immunofluorescence staining of C3 and MAC (green) on HK-2 cells exposed for 90 min to medium or 10% HS in the presence or absence of
soluble complement receptor-1 (sCR-1, 100 mg/ml). No C3 or MAC fixation was observed on unstimulated cells. HK-2 cells incubated with
10% HS exhibited C3 and MAC staining with granular distribution on cell surface (inset: two-fold enlargement of selected areas). sCR-1
treatment completely inhibited C3 and MAC signals. Living cells were stained in red using 5-(and-6)-(((4-chloromethyl) benzoyl) amino)
tetramethylrhodamine probe. Original magnification 630.
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We further explored to which extent albumin or
transferrin may promote active C3 deposition. Total C3b
and inactive C3b (iC3b) deposits were evaluated by using
antibodies (Abs) specific for C3c (present in both C3b and
iC3b molecules) or for iC3b fragments, respectively. Active
C3 deposition on cell surface was defined as ratio of C3c/
iC3b41. When cells were exposed to HS alone, the C3c/iC3b
ratio was 2.15±0.05 (Figure 2b). The addition of albumin
significantly increased active C3 deposits (3.60±0.09),
whereas transferrin had no significant effect as compared
with HS alone (2.41±0.06) (Figure 2b).
Then we investigated whether complement activation on
tubular cells by albumin and transferrin proceeded to the
formation of MAC. MAC fixation also further increased
(Po0.01) in cells exposed to albumin followed by the
addition of HS, as compared with exposure to HS alone
(Figure 2c), an effect that was not observed with transferrin
(Figure 2c). The viability of HK-2 cells was not altered by
24-h exposure to albumin or transferrin alone (albumin:
96.8±13.8, transferrin: 93.2±2.9 versus control: 100% viable
cells). No additional effect on cell viability was observed
when either proteins were given as pretreatment before 10%
HS (albuminþHS: 118.3±10.1, transferrinþHS: 83.9±4.4
versus control: 100% viable cells).
Albumin overload enhances fractalkine and TGF-b mRNA
upregulation induced by serum complement
To investigate the functional consequences of protein over-
load-induced activation of complement on HK-2 cells, we
studied the expression of fractalkine and transforming
growth factor-b (TGF-b), taken as markers of cell activation
and known mediators of tubulointerstitial inflammation and
fibrosis.28 Serum complement enhanced the expression of
both cytokines as reflected by combined findings of increased
fractalkine and TGF-b mRNA by 10% HS, and abrogation in
the presence of complement inhibitor sCR-1 (Figure 3). The
combination of HS and albumin challenge had additive
effects as shown by further significant (Po0.05) increases in
mRNA levels of both mediators as compared with each
stimulus alone. The exposure of cells to transferrin alone
caused fractalkine and TGF-bmRNA upregulation (Po0.05),
and no further increases were observed when combined with
HS (Figure 3).
Effects of protein load on factor H binding and production
To identify the mechanisms underlying the increased serum
C3 and MAC deposition on HK-2 cell surface in response to
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Figure 2 | Effect of plasma proteins on serum-induced C3 and
MAC deposition. (a) C3 deposits were quantified (pixel2 103) by
confocal microscopy on HK-2 cells preexposed to medium
(control), albumin (alb) or transferrin (transf) (10 mg/ml) for 24 h
followed by replacing with medium or 10% HS (90 min). (b) Active
C3 deposition was assessed in HK-2 cells exposed to the same
stimuli as above and expressed as the ratio of total C3 (C3c)/
inactive C3b (iC3b) deposit areas. (c) MAC deposits were
quantified (pixel2 103) on HK-2 cell surface by confocal
microscopy. Results are expressed as mean±s.e. (n¼ 7
independent experiments for C3 and MAC deposition, and n¼ 4 for
active C3 deposition). 1Po0.01 versus control, *Po0.01 versus HS.
Table 1 | Effect of MgCl2–EGTA and sCR-1 on C3 deposition in
HK-2 cells
C3 deposit area (pixel2)
 +MgCl2-EGTA +sCR-1
10% HS 4458±231 4770±251 26±11
Albumin +10% HS 8045±4831 8033±633 23±4#
Transferrin +10% HS 9716±14361 9939±1456 25±2y
Data are expressed as mean±s.e. of 15 fields for each sample (n=4).
1Po0.01 versus 10% HS, #Po0.01 versus albumin+10% HS, yPo0.01 versus
transferrin+10% HS.
HK-2 cells were exposed for 24 h to medium alone, albumin, or transferrin (10 mg/ml)
before incubation with 10% human serum (HS) for 90 min in the presence or
absence of MgCl2–EGTA (5 mM) or sCR-1 (100 mg/ml).
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protein overload, we focused on factor H, one of the main
natural inhibitors of the alternative pathway of complement,
which could act on proximal tubular epithelial cells. For this
purpose, we studied first whether resting HK-2 cells bind
factor H. Unstimulated HK-2 cells expressed low levels of this
complement regulatory protein (Figure 4). Exogenous
purified factor H added to HK-2 cells markedly bound to
the cell surface (Figure 4), as shown by the increased
percentage of fluorescent cells detected by flow cytometry
(Table 2). The binding of factor H on the cell surface was
decreased by pre-exposure of HK-2 cells to albumin or
transferrin (Figure 4 and Table 2).
To understand whether plasma proteins could affect
endogenous factor H synthesis, western blot analysis was
performed for detection of factor H production by HK-2 cells
exposed to medium alone, albumin, or transferrin for 24 h.
Unstimulated cells constitutively produced factor H, as
showed by detection in the cell supernatants of a band of
approximately 150 kDa, corresponding to factor H (see
Figure S1). This band was not detectable in supernatants
derived from HK-2 cells incubated with albumin or
transferrin (Figure S1), thereby indicating an inhibitory
effect of protein overload on factor H production by
proximal tubular cells.
Role of factor H in the control of active C3 and MAC
deposition
To define in our experimental setting the relation between
factor H binding and complement deposition, we first
assessed the level of active C3 deposits on tubular cells after
exposure to HS, a source of factor H in addition to
complement. Active C3 deposition was evaluated by flow
cytometry as the ratio C3c/iC3b. When HK-2 cells were
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Figure 3 | Effect of serum and protein overload on fractalkine
and TGF-b mRNA expression. Expression of fractalkine and
TGF-b mRNA evaluated by real-time PCR in HK-2 cells exposed to
10% HS with or without the complement inhibitor sCR-1 or
exposed to albumin (alb) or transferrin (transf) (10 mg/ml)
followed by medium or 10% HS. Data are relative values as
compared with control cells exposed to medium alone (dashed
line). Results are expressed as mean±s.e. of three independent
experiments. 1Po0.05 versus control, *Po0.05 versus HS,
#Po0.05 versus albumin.
Control
Albumin + FH Transferrin + FH
Control + FH
Figure 4 | Effect of plasma protein load on factor H binding to
HK-2 cells. HK-2 cells showed a weak granular staining (green) for
factor H (FH) on the cell surface as assessed by
immunofluorescence analysis. Strong staining for FH was
observed after incubation of the cells for 3 h with purified human
FH (10 mg/100 ml). Preexposure for 24 h to albumin (10 mg/ml) or
transferrin (10 mg/ml) significantly decreased the capability of
HK-2 cells to bind FH. Nuclei were counterstained in blue with
DAPI. Original magnification 630.
Table 2 | Plasma proteins decrease exogenous factor H
binding on HK-2 cells
Fluorescent cells (%)
 +Factor H
Control 23.35±1.44 37.87±0.931
Albumin 21.89±0.78 25.86±1.81**
Transferrin 27.19±1.19 29.28±3.90*
FACS analysis of factor H binding on cell surface. Results (mean±s.e.) are expressed
as % of fluorescent cells (n=8).
1Po0.01 versus control; *Po0.05, **Po0.01 versus control+factor H.
HK-2 cells were exposed for 24 h to medium (control), albumin, or transferrin. Then,
human factor H (10mg) was added for 3 h.
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exposed to HS, the mean fluorescence intensity (MFI) of C3c
was higher than iC3b MFI (Figure 5a) and the ratio C3c/iC3b
was 2.3±0.4 (Figure 5b). Active C3 level in this condition
results from a balance between complement activation
spontaneously occurring on cell surface and its inactivation
by factor H. Serum factor H was capable of binding to HK-2
cells, as showed by immunofluorescence staining of factor H
on tubular cell surface after 90-min HS exposure (data not
shown). The blockade of the factor H catalytic site by
pretreating HS with N22 Ab29 significantly impaired factor
H-dependent C3b inactivation leading to an increase of total
C3 (Figure 5a) and active C3 deposits as indicated by the
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Figure 5 | Role of factor H in the control of active C3 and MAC deposition on HK-2 cells. (a) Flow cytometric analysis of total C3 (C3c)
and inactive C3 (iC3b) deposition on HK-2 cells exposed to 10% HS for 90 min in the presence or absence of anti-factor H (FH) N22 Ab,
which blocks the catalytic site, or L20 Ab that inhibits the cell membrane-binding site (top). Histograms are representative of mean
fluorescence intensity (MFI) for C3c and iC3b (bottom). (b) Active C3 deposition is defined as ratio of C3c and iC3b MFI 41. Results are
expressed as mean±s.e. (n¼ 4 independent experiments). *Po0.05, **Po0.01 versus HS; 1Po0.05, 11Po0.01 versus HSþ irrel. (c) MAC
deposition was analyzed by confocal microscopy and quantified as pixel2 103 (dashed line represents control value). Results are expressed
as mean±s.e. (n¼ 3 independent experiments). #Po0.01 versus control, *Po0.01 versus HS; 1Po0.01 versus HSþ irrel. (d) Effects of anti-FH
Abs on purified FH binding to HK-2 cell surface. Blocking the FH catalytic site had no effect, in contrast to the marked inhibition obtained by
blocking FH cell binding site by L20 Ab. Original magnification 630. Irrel Ab, irrelevant antibodies (control).
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ratio C3c/iC3b¼ 5.0±0.3 (Figure 5b). Similarly, L20 Ab,
which blocks the factor H cell membrane-binding site,29
increased both total C3 (Figure 5a) and the C3c/iC3b ratio
(5.9±1.4) (Figure 5b), indicating more deposition of active
C3 on the tubular cell surface. In contrast, addition of
irrelevant control anti-CD13 Ab had no effects as compared
with HK-2 cells exposed to HS alone (Figure 5a and b).
The influence of factor H activity on the presence of MAC
deposits on HK-2 cells was also evaluated. The inhibition of
either the catalytic site or the cell-binding site of factor H by
using N22 and L20 Abs, respectively, significantly increased
the amount of MAC deposits on cell surface as compared
with cells incubated with HS either alone or plus control
irrelevant Ab (Figure 5c).
Immunofluorescence experiments showed no inhibitory
effects of N22 Ab on exogenous factor H binding to the cell
surface, which instead was almost completely prevented by
L20 Ab (Figure 5d). Both Abs showed no binding to the cell
surface in the absence of factor H (data not shown).
Protein load decreases heparan sulfate density responsible
for factor H binding to HK-2 cells
Polyanionic molecules and specifically cell-associated pro-
teoglycans are major binding sites for factor H, as shown by
studies in cell-free systems30 and endothelial cells.26,27 To
assess whether heparan sulfate residues could mediate factor
H binding to tubular cell surface, HK-2 cells were exposed to
an Ab against N-sulfated glucosamine residues of heparan
sulfate before the addition of factor H. In comparison with
cells exposed to factor H alone (Figure 6), a marked
reduction of factor H binding was observed in cells treated
with anti-heparan sulfate Ab (Figure 6). No decrease in factor
H binding was found in the presence of an irrelevant control
Ab (anti-CD26) that binds to a tubular epithelial surface
target (Figure 6).
To further characterize the effect of protein load on factor
H binding capability, we investigated by flow cytometry
whether plasma protein challenge could modify the surface
expression of heparan sulfate on HK-2 cells. Incubation with
albumin or transferrin for 24 h caused a significant reduction
of heparan sulfate on HK-2 cell surface as reflected by lower
mean fluorescence intensity in comparison with unstimu-
lated cells (Figure 7). To identify the possible mechanism(s)
by which plasma proteins lead to a reduction of heparan
sulfate residues on the HK-2 cell surface, we focused on
heparanase 1 (HPSE-1), an enzyme involved in the heparan
sulfate cleavage.31 Western blot analysis of HPSE-1 protein
expression was performed in protein cell lysates obtained
from HK-2 cells incubated for 15 h with medium (control),
albumin, or transferrin. HPSE-1 was constitutively expressed
in untreated cells (see Figure S2). In response to plasma
protein exposure, an increase in the level of the 65-kDa form
of HPSE-1 was observed and confirmed by densitometric
analysis (Figure S2).
Finally, we assessed whether heparan sulfate, by binding
factor H, may be implicated in its inhibitory activity on
complement activation on HK-2 cells. Treatment of cells with
a specific Ab blocking the heparan sulfate residues before HS
addition significantly increased active C3 (Figure 8a) and
MAC deposition (Figure 8b) as compared with cells exposed
to HS alone or to HS plus the irrelevant control Ab (Figure 8a
and b).
DISCUSSION
We established a model to evaluate the effects of sublethal
challenge by complement on proximal tubular epithelial cells
under conditions that mimic the renal tubule in proteinuric
nephropathy. This allowed us to investigate whether excess
plasma proteins may lead to proximal tubular cell dysfunc-
tion induced by the abnormal presence of complement as
found in the ultrafiltrate, and by which mechanisms.
Findings that albumin overload enhances the deposition of
serum-derived C3 on the cell surface through the alternative
pathway leading to enhanced assembly of MAC suggest a role
of excess proteins within the ultrafiltrate in facilitating the
activation of the complement cascade. In particular, these
data explain the high vulnerability of proximal tubular cells
to abnormal exposure to complement in chronic proteinuric
diseases. Along this line, C6 deficiency failed to significantly
impact on tubulointerstitial damage in nonproteinuric
models of renal disease, suggesting that in the absence of
proteinuria, C5-b9 was not sufficient to enhance injury.21 If
Control + FH FH + hep sulf Ab FH + irrel Ab
Figure 6 | Factor H binds to heparan sulfate residues on HK-2 cell surface. Immunofluorescence analysis of factor H (FH) binding to HK-2
cell surface. With respect to cells exposed to FH alone, a marked reduction of FH binding was observed in cells treated with an Ab
specifically recognizing heparan sulfate residues (hep sulf Ab). No decrease in FH binding was found in the presence of a control Ab
(irrel Ab). Nuclei were counterstained in blue with DAPI. Original magnification 630.
Kidney International (2009) 75, 1050–1059 1055
S Buelli et al.: Complement-activating environment by protein load o r i g i n a l a r t i c l e
translated in vivo, increased complement deposition and
activation by protein load on tubular cell surface may play a
pivotal role in exacerbating tubulointerstitial injury.
We previously documented that antiproteinuric treatment
by ameliorating the damage of the glomerular barrier to
proteins limits tubular and interstitial injury in chronic
proteinuric nephropathy.18–20 The reduced tubular overload
with filtered proteins and C3 was associated with reduced
proinflammatory activation of tubular cells, which could
account for renoprotective effects.18,19 In fact, the abnormal
exposure of proximal tubular cells to ultrafiltered C3 is a
major factor promoting tubulointerstitial injury in mice with
protein overload proteinuria even in the absence of local C3
synthesis.20 In light of these findings, protein overload and
activation of complement on luminal surface are strictly
interrelated processes, in line with the concept that chronic
proteinuria provides both a stimulus for C5b-9 assembly and
an environment favoring its sublytic effect. The latter
includes increased cytokine expression23 and upregulation
of collagen type IV by proximal tubular cells, contributing to
the fibrotic process in vivo.32 Here, both albumin and serum
complement upregulated fractalkine and TGF-b mRNA
expression, and in an additive manner when given in
combination. These findings indicate that albumin load-
enhanced complement activation acts to sustain proinflam-
matory and fibrogenic cellular phenotypic changes. The
evidence for protein and complement-induced TGF-b
upregulation reinforces the role of TGF-b signaling in
myofibroblast accumulation in the interstitium surrounding
proximal tubules engaged by ultrafiltered proteins.19 In
agreement with our data, the addition of serum or C3a and
C5a to human proximal tubular cells resulted in a fibrogenic
phenotype with increased a-smooth muscle actin and
collagen I expression, consistent with complement-dependent
epithelial–mesenchymal transition.33
The exposure to complement did not further enhance
transferrin-induced fractalkine and TGF-b gene upregula-
tion. This difference with respect to albumin was related to
the strong ability of albumin of enhancing active C3
deposition, as reflected by simultaneous increase in total C3
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Figure 7 | Protein load decreases heparan sulfate density on
HK-2 cell surface. Flow cytometry of heparan sulfate expression
measured by mean fluorescence intensity (MFI) in HK-2 cells
exposed to medium (control), albumin (alb), or transferrin (transf)
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Figure 8 | Role of heparan sulfate in serum-derived active C3
and MAC deposition. (a) Active C3 and (b) MAC deposition on
HK-2 cells treated with an anti-heparan sulfate Ab (hep sulf Ab)
or irrelevant Ab (irrel Ab) before the addition of 10% HS for
90 min. Results are expressed as mean±s.e. (n¼ 5 independent
experiments for active C3; n¼ 3 for MAC deposition). Dashed
line represents control value. #Po0.01 versus control, *Po0.01
versus HS; 1Po0.05, 11Po0.01 versus HSþ irrel.
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and reduction in iC3b, with increased total C3/inactive iC3b
ratio. Active C3 deposition is pivotal for C5b-9 generation
and complement-dependent injury. Molecular mechanisms
underlying this differential response were not further
characterized here and might include differences in albumin
and transferrin receptor affinity and/or downstream intra-
cellular events. It is noteworthy that albumin overload9 and
activated complement proteins stimulate cytokine expression
through the nuclear factor-kB-dependent pathway. This
response is most likely to be enhanced in the presence of
both C3a34 and C5b-9,35 which can be formed in excess upon
exposure to albumin but not transferrin load.
The second purpose of this study was to assess whether
protein overload may influence the capability of proximal
tubular cells to counteract complement activation by altering
their complement regulatory potential. We studied the role of
factor H, the main soluble inhibitor of alternative pathway
shown to be produced by human proximal tubular cells.24
Factor H binds to the cell surface serving as a cofactor for
factor I in the degradation of newly formed C3b to inactive
iC3b, thereby limiting the formation of C3 convertase.36
Here, the evidence for factor H binding to unstimulated
proximal tubular cells identifies this cell type as a novel
candidate target for its protective action. Moreover, cell-
bound serum-derived factor H limited active C3 and MAC
deposits on cell surface, which indeed were enhanced in the
presence of Abs blocking either the C-terminal cell
membrane-binding site or the catalytic site of factor H.
Importantly, surface-bound factor H may act as the main
shield against complement activation in proximal tubular
cells, which have no or very low expression of membrane-
anchored regulators, such as CR1, decay accelerating factor,
membrane cofactor protein, and CD59.37
Factor H is known to bind to few cell types, including
endothelial cells, through heparan sulfate/glycosaminoglycan
sites.25,27,38,39 Our data showing factor H binding to heparan
sulfate residues on the proximal tubular cell surface are in
agreement with the possibility that heparan sulfate chains may
behave as a polyanionic structure for factor H binding, as
suggested also by studies using cell-free systems.40,41 Moreover,
increased active C3 deposition upon blockade of heparan sulfate
residues reflects the ability of heparan sulfate–factor H
interaction to reduce complement deposition on HK-2 cells.
This function is impaired by protein overload at least partly
through a heparanase-1-mediated mechanism so as to enhance
the surface deposition of active C3. These results indicate that
protein overload alters proximal tubular cell phenotype by
reducing the ability of the cell to counteract complement
activation. The production of endogenous factor H was also
reduced in protein-overloaded cells in the absence of serum.
However, the importance of this effect in HK-2 cells here is not
clear, as it was not associated with an increase in endogenous C3
binding to the cell surface.
These findings have significant implications in renal
disease. First, the evidence that excess plasma proteins
prevent factor H binding to proximal tubular cells highlights
a potential mechanism underlying uncontrolled complement
activation at the tubular level. This would predict more
protection by targeting the tubule with complement
inhibitory molecules, such as soluble complement receptor-
1 and targeted-Crry and CD59, if given in combination with
antiproteinuric therapy.13,17 Second, investigation of factor H
in renal disease has been mostly confined to the pathogenetic
role of intravascular/intracapillary factor H loss or dysfunc-
tion.42,43 Notably, tubular cell injury has been suggested to
contribute to renal dysfunction in hemolytic uremic
syndrome,44 a disease often associated with factor H defective
activity. Impaired tubular cell protection against complement
activation may contribute to this disease process and possibly
to tubular injury in other settings in which ultrafiltered and/
or tubular cell-derived factor H could play a regulatory role.
MATERIALS AND METHODS
Cell culture and incubation
HK-2 cells, a human proximal tubular epithelial cell line45
(American Type Culture Collection, Rockville, MD, USA), were
grown as described previously.4 For a detailed description, see
Supplementary Methods. Confluent cells were maintained overnight
in Dulbecco’s modified Eagle’s medium/F-12 without serum before
the experiments. For immunofluorescence studies, experiments were
conducted on cells grown on glass coverslips (Bio-optica Milano
Spa, Milano, Italy). HS from a pool of plasma from five healthy
volunteers was used as a source of complement.
The concentration-dependent effect of HS on cell viability was
tested by incubation (90 min) with control medium (Dulbecco’s
modified Eagle’s medium/F-12 serum free), 10 or 25% HS. Viability
was assessed by trypan blue dye exclusion (Sigma, Chemical Co.,
St Louis, MO, USA). C3 and MAC deposits were assessed by
immunofluorescence in HK-2 cells incubated for 90 min with
control medium, 10% HS in the presence or absence of sCR-1
(100 mg/ml, Avant Immunotherapeutics Inc., Needham, MA, USA).
To visualize living cells, the cell tracker 5-(and-6)-(((4-chloro-
methyl) benzoyl) amino) tetramethylrhodamine (10 mM, Molecular
Probes Inc., Eugene, OR, USA) was added to the medium for 3 h
before 10% HS incubation. To investigate whether preexposure to
plasma proteins could potentiate HS cytotoxicity and complement
deposition, cells were incubated for 24 h with control medium,
human albumin (low endotoxin), or transferrin (10 mg/ml, Sigma,
Chemical Co., St Louis, MO, USA) followed by 10% HS stimulation.
C3 and MAC deposits were quantified by confocal microscopy. The
albumin and transferrin concentrations and time of exposure were
chosen on the basis of previous studies by us and other groups
reporting in vitro conditions that are most likely to mimic the
chronic proteinuric setting.4,5,9,46,47 In particular, we selected a high
dose of albumin to duplicate a condition reflecting severe and
prolonged injury of the glomerular barrier in which proteins with a
higher molecular weight, such as C3 (MW 185 kDa) and factor H
(MW 150 kDa), would become filtered and reach the tubule.
Experiments using a lower concentration of albumin (100 mg/ml)
before 10% HS addition showed no significant increase in C3
deposition as compared with the exposure to HS alone (control:
34±7; HS: 3668±639; HSA 100mg/mlþHS: 4031±710 pixel2).
To identify the activation pathway(s), HS was supplemented with
MgCl2–EGTA (5 mM, Sigma) or sCR-1 (100 mg/ml). Fractalkine and
TGF-b mRNA expression were assessed in cells exposed to medium
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or 10% HS, with or without albumin or transferrin preexposure.
The effect of 10% HS pretreatment with sCR-1 (100 mg/ml) was also
evaluated.
C3 and MAC immunofluorescence staining and flow
cytometry
Cells were fixed in 4% paraformaldehyde and 2% sucrose (20 min,
371C). For C3, HK-2 cells were incubated with fluorescein
isothiocyanate-conjugated rabbit anti-human C3c Ab (11.3 mg/ml,
Dako A/S, Glostrup, Denmark). MAC was detected by using rabbit
IgG anti-human C5b-9 Ab (27.6 mg/ml, Calbiochem, La Jolla, CA,
USA) for 1 h followed by fluorescein isothiocyanate-conjugated goat
anti-rabbit IgG (13.6 mg/ml, Jackson ImmunoResearch Laboratories,
West Grove, PA, USA). Fifteen fields per sample were randomly
acquired in a blinded manner using an inverted confocal laser
microscopy (LSM 510 meta; Zeiss, Jena, Germany). Digitized images
were binarized using a threshold for areas of staining corresponding
to C3 and MAC deposition. Fluorescent areas were calculated
automatically in pixel2 using analysis software Image J1.32.
Active C3 deposition on HK-2 cell surface was assessed by
confocal microscopy (see Supplementary Methods) and by flow
cytometry (FACSort, Becton-Dickinson, San Jose, CA, USA). Briefly,
HK-2 cells were exposed for 90 min to 10% HS in the presence or
absence of the anti-factor H blocking Abs N22 and L20 (mouse
IgG1, 10mg/ml)29 against the catalytic site and cell membrane-
binding site of factor H, respectively. Cells were detached and
stained with either fluorescein isothiocyanate-conjugated anti-
human C3c Ab or with mouse monoclonal anti-iC3b (10 mg/ml,
Quidel, San Diego, CA, USA) followed by fluorescein isothiocya-
nate-conjugated secondary Ab. As an irrelevant control Ab, mouse
anti-CD13, which binds to the tubular epithelial cell surface, was
used (IgG1, 10 mg/ml, AbD Serotec, Oxford, UK).
Statistical analysis
Results are expressed as mean±s.e. Statistical analysis was
performed using analysis of variance followed by Tukey’s test for
multiple comparisons or nonparametric Kruskal–Wallis test.
Statistical significance level was defined as Po0.05.
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